Definitive Radiotherapy With or Without Chemotherapy After Planned Neoadjuvant Chemoimmunotherapy in Stages II to III NSCLC: An International Multicenter Retrospective Study
{{output}}
Introduction: Approximately 15% to 20% of patients with resectable NSCLC receiving neoadjuvant chemoimmunotherapy on clinical trials cannot proceed to surgery due to disease progression, toxicity, or medical contraindications. Th... ...
